PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 12, 2025Biomolecules8 citationsOpen Access

Natural Compounds as Modulators of Ferroptosis: Mechanistic Insights and Therapeutic Prospects in Breast Cancer

View Full Paper
HHHua HeHYHaoyang YuHZHefeng Zhou

Key Points

  • Ferroptosis induction via natural compounds can reduce breast cancer metastasis and improve patient outcomes.
  • Several natural products act as ferroptosis sensitizers, enhancing the effectiveness of cancer therapies.
  • This thorough review assesses mechanisms by which natural compounds trigger ferroptosis in breast cancer models.
  • The findings indicate potential barriers for clinical translation and highlight the need for further exploration.

Abstract

Breast cancer is the most prevalent malignant tumor in women. However, its clinical management is severely hindered by three interconnected challenges that limit long-term survival: treatment resistance, metastatic dissemination, and immunological evasion. Ferroptosis, an iron-dependent form of regulated cell death, is emerging as a novel strategy to overcome these obstacles. Furthermore, it demonstrates significant potential in inhibiting tumor metastasis and modifying the anti-tumor immune microenvironment, which provides a novel approach to address the core dilemma of breast cancer. Natural products have emerged as significant sources of ferroptosis inducers owing to their distinctive chemical variety, multi-target regulatory capabilities, and acceptable safety profile. Data increasingly indicates that several natural compounds can function as effective inducers or sensitizers of ferroptosis cell death. This review provides a thorough evaluation of current progress in harnessing natural ingredients to trigger ferroptosis for breast cancer treatment. It also elucidates the fundamental molecular mechanisms. Furthermore, it encapsulates therapeutic efficacy in preclinical models. Ultimately, it rigorously evaluates existing constraints and delineates potential and barriers for clinical translation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

He et al. (2025) studied this question.

synapsesocial.com/papers/68d44b2231b076d99fa540d0https://doi.org/10.3390/biom15091308
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cycloplatinated (II) Complex Based on Isoquinoline Alkaloid Elicits Ferritinophagy-Dependent Ferroptosis in Triple-Negative Breast Cancer Cells2024 · 32 citations
  2. 2Mutant p53 reactivators protect breast cancer cells from ferroptosis2024 · 3 citations
  3. 3Formononetin triggers ferroptosis in triple-negative breast cancer cells by regulating the mTORC1/SREBP1/SCD1 pathway2024 · 21 citations
  4. 4Notoginsenoside R1 (NGR1) regulates the AGE-RAGE signaling pathway by inhibiting RUNX2 expression to accelerate ferroptosis in breast cancer cells2024 · 12 citations
  5. 5Exploring natural products for allosteric inhibition of glutathione peroxidase 4 in drug-resistant cancers via molecular docking and dynamics2025 · 5 citations